Cardiologists debated Saturday whether GLP-1 weight-loss medications reduce physical activity enough to offset metabolic gains from shedding pounds.
Drugs such as semaglutide curb appetite dramatically, leading some patients to skip structured exercise they previously tolerated.
Studies tracking step counts show mixed results, with highly motivated users maintaining routines while others become more sedentary.
Doctors recommend pairing prescriptions with resistance training to preserve muscle mass during rapid weight decline.
Insurance plans increasingly cover GLP-1 therapies for obesity, raising population-level questions about long-term fitness benchmarks.
Researchers plan registries capturing heart-rate variability and VO2 metrics to settle whether leaner bodies always mean healthier cardiovascular profiles.
Employers adding GLP-1 coverage to wellness plans said they may require concurrent coaching sessions to maintain muscle mass during rapid weight loss.
Fitness industry analysts noted gym memberships among medicated patients fell in some markets, raising questions about long-term revenue models for boutique studios.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/